Moonshot AI Wraps Its Pre-IPO Round at a $50 Billion Valuation and Targets a Hong Kong Listing in Early 2027

Moonshot AI, the Beijing laboratory behind the Kimi model family, has completed the final private funding round before a planned public listing, at a valuation of roughly $50 billion, Bloomberg reported Monday, citing people familiar with the matter. The company is now pushing toward an initial public offering in Hong Kong in the first quarter of next year.

According to the anonymous sources, Moonshot has already begun preparations to gauge investor interest, with preliminary talks potentially starting as early as this month. The company is considering raising up to $5 billion in the listing. Both the timing and the size remain fluid — the people stressed that discussions are ongoing and the IPO could slip. Moonshot has not publicly confirmed any of the details.

The valuation is the headline, but the revenue curve underneath it is what makes the number discussable. Bloomberg's earlier reporting put Moonshot's annualized recurring revenue above $1 billion in August 2026, up from roughly $300 million in June — a jump the company attributes to Kimi K3, released in July. An internal target reported at the time calls for doubling to $2 billion in annualized sales by the end of 2026. Even at the upper bound, that leaves a $50 billion valuation pricing in years of continued hypergrowth.

Moonshot's rise tracks the broader open-weight playbook that has reshaped the market this year: Chinese labs shipping cheaper, customizable models that enterprises can host themselves, forcing closed labs to defend on price. Its nearest local benchmarks tell the story — Z.ai has been reported at a comparable $50 billion valuation, while MiniMax posted about $800 million in annualized recurring revenue in August.

The listing will also carry baggage. Anthropic has accused Moonshot of distilling its Claude outputs, and in late September OpenAI said it had disrupted a coordinated model-distillation campaign it attributed to individuals associated with Moonshot — a characterization the company has disputed. None of it has visibly slowed the funding round, but public-market investors will ask harder questions than private ones about provenance, licensing exposure and the sustainability of a price advantage built partly on cheaper training.

If the listing lands in the first quarter as planned, Moonshot would become one of the largest Chinese AI IPOs to date, testing how much of the private-market enthusiasm for open-weight labs transfers to public investors. Hong Kong has already become the default venue — 22 of the 23 AI companies that went public in China in the first half of 2026 chose it. A $50 billion Kimi listing would raise the stakes for everyone else still queuing.